Evozyne

AI-engineered proteins for immune-mediated disease

Chicago, United States · Founded 2020 · $135.2M raised

Headquarters
Chicago, Illinois
Employees
51–200
Founded
2020
Business Model
B2B
Total Funding
$135.2M
Last Round
$81.0M Series BSep 2023
Rounds
2

About

Evozyne is an AI-native biotech company that designs novel engineered protein therapeutics to address immune-mediated diseases. Founded by Paragon Biosciences, the company uses generative deep learning and high-throughput biology to create proteins with mechanisms that natural evolution never produced. Based in Chicago, Evozyne collaborates with partners including NVIDIA to accelerate the path from protein design to clinical application.

Summary

Evozyne is an Artificial Intelligence company based in Chicago, United States, founded in 2020. It has raised $135.2M in total across 2 rounds, most recently a $81.0M Series B round in Sep 2023. Investors include OrbiMed, Fidelity Management and nVentures.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Series BSeries BSep 2023
$81.0M

Sign up to see all 2 rounds

Series A through Series B — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Evozyne on Indexed.vc
<a href="https://indexed.vc/companies/evozyne"><img src="https://indexed.vc/api/badge/company/evozyne" alt="Evozyne on Indexed.vc" width="260" height="76" /></a>